Phillip Bertrand Berkey Moheno
SanRx Pharmaceuticals Inc., USA
Keynote: Virol Mycol
Calcium folate is the excess calcium salt of the vitamin folic acid. Folic acid is sensitive to acidic-oxidative conditions and in the presence of excess Ca+2 as well, is transformed into pterins and calcium pterins. This pilot observational study describes the use of CaFolate-derived calcium pterin 6-carboxylate in the treatment of certain immune-related ailments. Patients with various immune-associated disorders were directed to take ad libitum 25-76 mg of CaFolate (300-900 Ã?Â¼g folic acid equivalents) orally per day, as an adjuvant therapy and to collect personal and medical assessments. The users reported no flu/colds (>20/20 reporting none during the cold and flu season), greater energy/stamina (8/8 reporting increased), less osteoarthritis pain (10/11 reporting improvement), diminished mouth sores due to chemotherapy (2/2 reporting significant clearance) and cancer remissions (4/5 reported plus 1 transient improvement in a terminal case). These observational findings identify certain clinical endpoints for future matched group, randomized, double-blind, placebo-controlled clinical trials. One such clinical trial is underway in osteoarthritis.
Phillip Bertrand Berkey Moheno holds a BS degree and a PhD in Confluent Education from the University of California, Santa Barbara. He has more than 20 years of research experience in the anti-cancer properties of pterins. He has published 12 papers in reputed journals.
Email: [email protected]